Catalyst Biosciences Inc (NASDAQ:CBIO) announced recently that they have successfully achieved the positive clinical data from its ongoing Phase 1/2 clinical data in the participants with severe hemophilia B condition. The team was excited by the results that showed the higher potency and advanced pharmacokinetics of CB 2679d. The findings have numerous advantages over the […]
